Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Cyclo Therapeutics, Inc.
< Previous
1
2
Next >
Cyclo Therapeutics Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1)
October 18, 2022
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Commences Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s Disease
October 04, 2022
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Provides Business Update
September 28, 2022
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 07, 2022
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
August 16, 2022
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics to Present at the China NPC Association Meeting
August 08, 2022
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics to Present at the NNPDF-INPDA Conferences 2022
July 21, 2022
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics to Present at the World Orphan Drug Congress USA 2022
July 11, 2022
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics to Present at the 2022 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation
June 21, 2022
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
May 18, 2022
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
May 12, 2022
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics to Participate in the Virtual Investor Niemann-Pick Disease Type C Spotlight Event
May 09, 2022
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics to Participate in the Virtual Investor Alzheimer’s Disease Spotlight Event
March 29, 2022
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Enters Research and Collaboration Agreement with Wits Commercial Enterprise (Pty) Ltd to Explore Potential Applications of Trappsol® Cyclo™ to Expand Pipeline
March 24, 2022
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
March 23, 2022
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Provides Business Update and Reports Full Year 2021 Financial Results
March 14, 2022
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Selected to Present Overview of Pivotal Phase 3 Study for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2022
February 08, 2022
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Announces Formation of Global Steering Committee Comprised of Leading Experts to Advise on the Global Phase 3 Clinical Development Program for Trappsol® Cyclo™ in Niemann-Pick Disease Type C
February 03, 2022
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics to Present at the Virtual Investor 2022 Top Picks Conference
January 20, 2022
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Appoints Caroline Hastings, M.D. as Global Principal Investigator for Ongoing TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease
December 09, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease
December 06, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Announces Pricing of $11.7 Million Underwritten Public Offering of Common Stock
November 16, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Announces Proposed Public Offering of Common Stock
November 16, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
CYTHW
Cyclo Therapeutics Submits Investigational New Drug Application to U.S. FDA to Advance Trappsol® Cyclo™ in Phase 2 Study for Treatment of Alzheimer’s Disease
November 16, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
November 15, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics to Present at the Virtual Investor Roundtable Event
November 10, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Names Preeminent Neuroscientist and World-Renowned Researcher, Cynthia A. Lemere, PhD, as Senior Advisor for Advancement of Alzheimer’s Disease Asset
November 02, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Recognizes Niemann-Pick Disease Awareness Month Highlighting Need for Broader Awareness and Support for Research to Find a Treatment
October 19, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the 14th International Congress of Inborn Errors of Metabolism (ICIEM)
October 18, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics to Participate in the 2021 Virtual Cyclodextrin Conference Hosted by CycloLab
October 06, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.